AUTL
NASDAQ
$1.75
Autolus Therapeutics plc (AUTL)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $8.71 (+397.71%)
Market Cap
$447M
Free Cash Flow Yield
-64.54%
Beta (5Y)
1.30
Price Chart
Valuation
Market Cap$447M
P/S461.46
P/B4.60
Profitability
Total Revenue (TTM)$93M
Gross Profit (TTM)-$26M
EBITDA-$256M
Operating Margin-6571%
EPS-$1.01
Financial Health
Free Cash Flow Yield-64.54%
Growth & Risk
Beta (5Y)1.30
Sharpe Ratio0.33